FXYD7 Rabbit Polyclonal Antibody
CAT#: TA376402
FXYD7 Rabbit polyclonal Antibody
Size: 20 ul
Need it in bulk or conjugated?
Get a free quote
CNY 1999.00
CNY 3280.00
货期*
2周
规格
推荐一起购买 (1)
Specifications
Product Data | |
Applications | ELISA, WB |
Recommend Dilution | WB,1:500 - 1:2000 ELISA,Recommended starting concentration is 1 μg/mL. Please optimize the concentration based on your specific assay requirements. |
Reactivity | Mouse, Rat |
Modifications | Unmodified |
Host | Rabbit |
Clonality | Polyclonal |
Isotype | IgG |
Formulation | Buffer: PBS with 0.01% thimerosal,50% glycerol,pH7.3. |
Concentration | lot specific |
Purification | Affinity purification |
Conjugation | Unconjugated |
Storage Condition | Store at -20℃. Avoid freeze / thaw cycles. |
Predicted Protein Size | 9kDa |
Gene Name | FXYD domain containing ion transport regulator 7 |
Database Link | |
Background | This reference sequence was derived from multiple replicate ESTs and validated by similar human genomic sequence. This gene encodes a member of a family of small membrane proteins that share a 35-amino acid signature sequence domain, beginning with the sequence PFXYD and containing 7 invariant and 6 highly conserved amino acids. The approved human gene nomenclature for the family is FXYD-domain containing ion transport regulator. Transmembrane topology has been established for two family members (FXYD1 and FXYD2), with the N-terminus extracellular and the C-terminus on the cytoplasmic side of the membrane. FXYD2, also known as the gamma subunit of the Na,K-ATPase, regulates the properties of that enzyme. FXYD1 (phospholemman), FXYD2 (gamma), FXYD3 (MAT-8), FXYD4 (CHIF), and FXYD5 (RIC) have been shown to induce channel activity in experimental expression systems. This gene product, FXYD7, is novel and has not been characterized as a protein. [RefSeq curation by Kathleen J. Sweadner, Ph.D., sweadner@helix.mgh.harvard.edu., Dec 2000] |
Synonyms | FLJ25096 |
Reference Data |
Documents
Product Manuals |
FAQs |
SDS |
Resources
抗体相关资料 |
Customer
Reviews
Loading...